Actively Recruiting

Age: 18Years +
All Genders
NCT05743140

A Clinical Study of Fundus OCTA for the Identification of CMD

Led by Peking University First Hospital · Updated on 2025-08-12

400

Participants Needed

1

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.

CONDITIONS

Official Title

A Clinical Study of Fundus OCTA for the Identification of CMD

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital
  • Complete baseline clinical information
  • Coronary angiography results showing coronary stenosis less than 50%
  • Older than 18 years
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Present serious fundus disease
  • Severe cataract or other eye diseases affecting imaging quality
  • Target coronary vessels provide collateral circulation for chronic complete occlusive lesions
  • Poor filling, overlapping, or severe distortion of target coronary angiography agent preventing lesion location exposure
  • Poor quality coronary angiography images that cannot be identified
  • Active bleeding state
  • Severe renal insufficiency, contrast agent allergy, or inability to perform coronary angiography

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking university first hospital

Beijing, Beijing Municipality, China, 10034

Actively Recruiting

Loading map...

Research Team

B

Bo Zheng, Dr

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here